Gri Bio, INC 10-Q quarterly reports

GRI Bio, Inc. (GRI) filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing clinical development for its lead candidate GRI-0621 and highlighting significant financial challenges, including substantial doubt about its ability to continue as a going concern.

GRI Bio, Inc. (GRI) reported its first quarter 2026 financial results, highlighting progress in its clinical-stage biopharmaceutical development, particularly with its lead candidate GRI-0621 for fibrotic lung diseases.

GRI Bio reported increased net losses and a declining cash position, raising substantial doubt about its ability to continue as a going concern, despite progress in clinical trials and recent capital raises.

GRI Bio reports increased net losses and a going concern warning, despite recent capital raises and progress in its lead clinical program.

GRI Bio, Inc. announces its financial results for the first quarter of 2025, highlighting ongoing clinical trials for GRI-0621 and efforts to secure additional funding.

GRI Bio, a clinical-stage biopharmaceutical company, announced its financial results for the third quarter of 2024, highlighting ongoing clinical trial progress and recent financing activities.

GRI Bio, a clinical-stage biopharmaceutical company, announced its financial results for the second quarter of 2024, highlighting progress in its clinical programs and recent financing activities.

GRI Bio reported a net loss of $1.887 million for the first quarter of 2024, alongside updates on their clinical programs and recent financing activities.